Increased skin lymph protein clearance after a 6-h arterial bradykinin infusion.
When bradykinin (0.15-0.28 micrograms.kg-1.min-1) was infused into both femoral arteries of 11 anesthetized dogs, skin lymph flows increased by 25-371% within 2 h, and mean lymph protein concentrations increased by one-third. To determine whether, in addition to the initial increase in permeability, a 6.5- to 10-h bradykinin infusion caused a sustained effect, the bradykinin infusion into one hindpaw was stopped after 2 h (2HR), whereas the contralateral hindpaw was infused continuously (CONT). Two hours after the bradykinin infusion was stopped, Ringer lactate equal to 10% of the dog's body weight was given intravenously to further increase lymph flow. After Ringer lactate infusion, increase in lymph protein clearance from the CONT hindpaws was greater than that from the 2HR hindpaws (change in clearance from before Ringer lactate infusion to final: 2HR, 6.9 +/- 1.4 to 8.8 +/- 1.1; CONT, 23.4 +/- 2.5 to 40.2 +/- 4.8 microliters/min). In the final lymph samples of the CONT, but not 2HR, hindpaws, the lymph-to-plasma ratio for immunoglobulin G and immunoglobulin M divided by the albumin lymph-to-plasma ratio exceeded the value of these ratios in the base-line samples. An intravenous bolus of Evans blue dye was given less than 2 h before the end of the experiment. The concentrations of dye in the final lymph samples were greater in CONT hindpaws (12.6 +/- 3.7% plasma equivalents) than in the 2HR hindpaws (1.1 +/- 0.5%). A continuous 6.5- to 10-h intra-arterial bradykinin infusion produced a sustained increase of transvascular protein clearance in skin that is consistent with a sustained increase in microvascular membrane permeability.
Mullins
R J
RJ
Department of Surgery, University of Louisville Medical School, Kentucky.
Hudgens
R W
RW
D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage* / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects; D004285:Dogs; D005263:Femoral Artery; D007261:Infusions, Intra-Arterial; D008196:Lymph / Q000378:metabolism*; D008208:Lymphatic System / Q000502:physiology; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D011506:Proteins / Q000378:metabolism*; D012212:Rheology; D012867:Skin / Q000378:metabolism*
D011506:Proteins; D001920:Bradykinin